Succeed with Risk Sharing Agreements (RSAs)

Summary

Is a different approach to pricing agreements between pharma and payers a viable path to faster market introduction of new, innovative medicine such as ATMP? What problems do we solve with outcome-based risk sharing agreements and what are the opportunities (and challenges) for patients, society, and the pharma industry?

Outcome-based risk sharing agreements (OBRSAs) are not a new phenomenon. Yet risk sharing pricing agreements are still quite rare, among other because of a high level of complexity and limited experiences to date.

The one day course is based on Danish market conditions and Danish data, but we will discuss use of risk sharing agreements (RSAs) in an international and global perspective. We also showcase the new possibilities for data access via European Health Data Space (EHDS).

You’ll leave this course with in-depth knowledge about risk sharing agreements both in Denmark and the EU. You’ll be familiar with specific agreement types and know how to assess when outcome-based (OBRSAs) risk sharing agreements are particularly effective both from a payer  and industry perspective. Last, but not least, you will be introduced to how to get started with RSAs.  

Keywords

• Outcome-based pricing agreement (OBRSAs)
• Risk sharing agreements (RSAs)
• RWD/real world data
• Market access
• European Health Data Space (EHDS)